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Abstract
Background—The reasons for minority underrepresentation in HIV/AIDS clinical trials remain
unclear. We aimed to evaluate the knowledge, experience and factors that influence minority
participation in HIV/AIDS studies in the US.
Methods—An anonymous, bilingual, self-administered survey on study participation was given
to HIV-infected adults attending AIDS Clinical Trials Group-affiliated clinics in the US and
Puerto Rico. Chi-square tests were used to evaluate differences by race/first language/level of
education. Logistic regression was used to estimate odds ratio (OR) and 95% confidence interval
(CI) for factors associated with being talked to about participation in a study.
Results—We analyzed 2,175 complete surveys (221 in Spanish). Among respondents, 31% were
White, 40% black/African American (AA) and 21% Hispanic. The overall rate of previous
participation in any HIV/AIDS study was 48%. Hispanics were less likely to know about studies
compared to whites and AAs (67% vs. 74% and 76%; p<0.001). Compared to whites, AAs and
Hispanics were less likely to have been talked to about participating in a study (76% vs. 67% and
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67%; p<0.001). The OR for being talked to about participating in a study was 0.65 (95% CI: 0.52–
0.81) for AAs and 0.65 (95% CI: 0.49–0.85) for Hispanics, compared to whites. AAs and
Hispanics were more likely to state that studies were not friendly to their race (17% and 10% vs.
4%; p<0.001).
Conclusions—Minorities continue to face barriers for HIV/AIDS trial participation, even when
clinical research is available. Enrollment strategies should better target minorities to improve
recruitment in HIV/AIDS research.
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Background
Despite being disproportionately affected by the human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS) in the United States (US), minorities continue to
be underrepresented in HIV/AIDS clinical trials. This critical issue limits our understanding
of how applicable treatment outcomes are to the general population and lessens the potential
benefits of clinical research to all members of society.1,2,3,4 The reasons for minority
underrepresentation in clinical research are varied and complex; some of them are common
to all minority groups (i.e. lack of information and access to trials, provider bias on
adequacy of trial enrollment, competing family and financial priorities, low levels of
education, lack of health insurance and negative family and community opinions about
research),3,5 while others are specific to a certain minority groups (i.e. mistrust from
African-American community, language barriers in Hispanic immigrants).4,6,7 Many of the
studies that have evaluated the reasons that prevent minorities from enrolling in HIV/AIDS-
related clinical trials have focused on a single site1,8 or have studied populations with
limited access to clinical trials.4 Thus, there is a critical need for further research to
understand the knowledge and attitudes that HIV-infected minorities in the US have towards
participation in HIV/AIDS clinical trials.
The AIDS Clinical Trials Group (ACTG) is a long-standing network of domestic and
international research sites that conduct HIV/AIDS clinical trials.9 It includes a network of
47 domestic sites located in all 4 US regions (Northeast, South, Midwest and West) and
Puerto Rico. In many of these settings, clinical care and research facilities are co-located,
while they may be separate in others. These sites include University-based HIV clinics,
Public Hospital clinics and Community Health Centers, with a varied payor mix of insured/
uninsured patients according to the specific site. The primary objective of our study was to
describe and evaluate the knowledge, experience and factors that influence minority
participation in HIV/AIDS clinical trials among patients attending ACTG-affiliated clinical
sites. To address our objective we conducted a self-administered survey on HIV/AIDS trial
participation at clinical centers associated with the ACTG in the US and Puerto Rico.
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Survey distribution and content
The ACTG Underrepresented Populations Committee (UPC) developed the survey, which
was available both in English and Spanish (Appendix). The survey was developed de novo
and piloted in 5 ACTG sites covering 4 geographical areas of the US. In this pilot, a total of
100 surveys were distributed to the sites, of which 93 were completed and returned for
analysis. All 47 domestic ACTG sites were then invited to participate in the survey through
an e-mail memorandum from the ACTG Executive Committee Leadership. Site participation
was completely voluntary. Participating sites were sent a total of 60 surveys in English and
12 in Spanish, but the number of Spanish surveys sent could be increased upon a specific
site request. The sites were asked to distribute the surveys over a period of five months, with
a goal of obtaining 50 completed surveys per site. All sites obtained the approval from their
local institutional review board before initiating the study.
HIV-infected individuals who were 18 years and older and were attending the clinic or
research center for regular medical care were approached for participation by the ACTG
personnel (research nurse or research coordinator) or clinic staff. Sites were encouraged to
over represent women and minorities (when feasible) to allow for a diverse sample that
would be more representative of the demographics of the HIV epidemic in the US. Evidence
of HIV infection in the medical record was required for participation. The survey was an
anonymous, 7-page questionnaire written at a 6th grade reading level, which spanned 34
items in 3 categories: a) demographics; b) participation in and perceptions about clinical
trials, and; c) behaviors. If an individual agreed to participate, she/he was given a paper copy
of the survey and a letter-sized envelope labeled with a number. The questionnaire clearly
stated that the information from the survey was strictly confidential and that the answers
would not be shared with the participant’s health care provider(s). The participant then
completed the survey confidentially, usually in a private room. Participants could receive
assistance if they had problems reading the survey or if they had any questions regarding the
survey. Once completed, the participants placed the completed survey inside of the provided
envelope, sealed it, and gave it to the research nurse or coordinator. Sites were provided
with pre-addressed return shipping labels and were requested to return all completed surveys
to the ACTG Data Management Center by the end of the enrollment period. Sites that did
not adhere to this protocol were excluded from the analysis.
Statistical analysis
Chi-square tests were used to evaluate differences in responses to survey questions by race,
first language and level of education. No adjustments were made for multiple comparisons
in this descriptive study (some p-values could have resulted to be significant by chance).
Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI)
for demographic and behavioral factors associated with ever being talked to about
participation in a clinical trial. Demographic factors included age, sex, race, education and
first language. Behavioral factors included tobacco use, alcohol use and substance use.
Univariate models were used to assess the unadjusted ORs between the factors stated above
and being talked to about participating in a clinical trial. Variable that were significant
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(p<0.05) at a univariate level were added to the multivariable model. Age, sex and first
language were included in the multivariable model regardless of their p-value. For all other
variables, only those with p<0.05 were retained in the multivariable model. All analyses
were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Race was determined according to participant self-identification as white, black/African
American, Hispanic/Latino, Asian, Native American, American Indian, Alaska Native,
Native Hawaiian/other Pacific Islander or other. For the adjudication of race among
individuals who selected two races, Hispanic and any other race was coded as “Hispanic”,
black/African American and any other race (other than Hispanic) was coded as “black/
African American”, white and any other race (other than Hispanic or black/African
American) was coded as “white”. Respondents who checked 3 or more races or who added
in another race category, without having also checked black/African American or Hispanic/
Latino, were coded as “Other/Mixed race.”
Results
We distributed surveys to a total of 47 sites and received 2,263 completed surveys from 42
sites, 2,175 of which were included in the analysis (five sites did not return any surveys).
We excluded 88 surveys from two sites due to protocol violations. Of the 2,175 surveys, 221
surveys were in Spanish. The demographic characteristics of the 2,175 patients who
responded to the analyzed surveys are shown in Table 1.
Knowledge, Interest and Participation in HIV/AIDS clinical trials
No differences between male and female participants were observed in any of the evaluated
survey questions. The overall rate of previous participation in any HIV/AIDS clinical trial
among all individuals surveyed was 48% for both men and women. In Table 2 we present
results on the knowledge about availability, intention to participate, being approached for
participation, attempted participation, and previous active participation in HIV/AIDS
clinical trials according to race, first language and level of education. Compared to whites
and black/African-Americans (AAs), Hispanics were less likely to know about available
studies. AAs and Hispanics were less likely to have been talked to about participating, have
thought about participating, have tried to enroll and have actively participated in a study
when compared to whites. Subjects who identified Spanish as their first language were less
likely to know about available studies compared to English speakers, but did not show
significant differences in any of the other questions in this section.
The differences in trial interest and participation according to level of education were also
evaluated. Participants who had higher levels of education (some college/completed college/
graduate school) were more likely to know about, to consider participating, to have been
told about, to have tried to participate or have actively participated in a clinical trial
compared to individuals with a high school education or less. Similarly, in the multivariate
analysis, individuals with some college/technical school and college graduates were more
likely to have been approached to participate in a clinical trial (adjusted OR 1.57; CI:1.06–
2.33 and 1.68; CI:1.12–2.51, respectively)
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Experience during previous participation in HIV/AIDS clinical trials
Table 3 shows the experiences of 1,294 individuals who reported previous participation in
an HIV/AIDS clinical trial (defined as a combination of “tried to be in a study” and “ever
been in a study”). Hispanics were more likely to believe that participating in a trial made
them healthier when compared to whites and AAs. This was also observed when we
compared Spanish to English speakers and individuals with an elementary school education
to more educated patients. Spanish speakers were also more likely to believe that
participating in a clinical trial helped them get better medical care, as were individuals with
more than a high school education. When compared to Hispanics and AAs, whites were
more likely to report that participating in a study made them feel like they were helping
others, which was also observed when we compared highly educated participants to those
with lower levels of education. Overall, a small proportion of individuals (<5%) stated that
participating in an HIV/AIDS clinical trial made them feel worse or made them feel less
connected with their primary care provider (data not shown).
Factors that influence participation in HIV/AIDS clinical trials
Factors that would encourage or prevent individuals from enrolling in a research study,
regardless of whether they have participated or not in the past, are presented in Table 4.
Whites and AAs were more likely to enroll in a clinical trial to help fight HIV/AIDS when
compared to Hispanics, but Hispanics and AAs, and Spanish speakers were more likely to
enroll in a study to get better healthcare when compared to whites and English speakers,
respectively. AAs and Hispanics reported that they would be more willing to enroll in a
study to represent their race when compared to whites. Spanish speakers were less interested
in enrolling in a study to help fight HIV/AIDS or to obtain monetary compensation
compared to English speakers. Individuals with a college/post-graduate education were more
likely to participate in a clinical trial to help fight HIV/AIDS compared to individuals with
an elementary school education.
Hispanics and AAs were more likely to state that studies were not friendly to their race and
were more likely to avoid participation because they did not understand clinical trials when
compared to whites. This was also observed in high school graduates, who reported not
understanding the studies more frequently when compared to college/post-graduates.
Hispanics and AAs were more concerned about a breach in confidentiality and of being a
“guinea pig”, while white participants were more worried about getting placebo as the main
reason to avoid a clinical trial. Overall, only a small proportion of individuals reported
religious beliefs as the reason to avoid clinical trial participation (data not shown).
The multivariate analysis of factors associated with being talked to about participation in an
HIV/AIDS clinical trial is presented in Table 5. The unadjusted OR for being talked to about
participation in a study for individuals with some college/technical school or with a college/
post-graduate degree were 1.67 (95% CI: 1.15, 2.43) and 1.89 (95% CI: 1.29–2.77),
respectively, when compared to individuals with an elementary school education. This
remained significant after adjusting for age, sex, race, first language and active tobacco use.
Minority racial background was also associated with lower OR of being talked to about
participation in a study when compared to white race; the unadjusted OR was 0.65 (95% CI:
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0.52–0.81) for AAs and 0.65 (95% CI: 0.49–0.85) for Hispanics, which remained significant
for AAs after adjusting for age, sex, education, first language and active tobacco use.
Discussion
In this study, we performed an anonymous cross-sectional survey of HIV-infected patients at
ACTG clinical sites. Our results demonstrate a moderately robust (48%) rate of previous
participation in any HIV/AIDS trial in this setting. However, it also reveals persistent
minority underrepresentation in HIV research, even in an environment in which knowledge
on the availability of HIV clinical trials is expected to be higher than the general HIV-
infected population. Enrollment in a clinical trial is a process that requires active roles by
both patients and researchers at multiple steps, from the potential participant’s awareness
and intention to join a study to the researcher’s function as an unbiased enrollment facilitator
for all possible participants.8,10,11,12 In our data, the underrepresentation of racial minorities
was evident at all levels of the research participation continuum: knowledge of trials,
intention to participate, being approached by research team, effort to enroll, and successful
enrollment. Our findings are consistent with results from a CDC-based study by Sullivan, et
al, which found an OR of 0.6 for trial participation in black and Hispanic men compared to
white men among 5,010 interviewees in 15 US states.4 In that study, overall participation of
HIV-infected individuals was 17% among men and 15% among women, which is similar to
the 14% clinical trial participation in a representative sample of all HIV infected patients in
care within the US previously reported by Gifford, et al2, but low when compared to the
48% found in our survey. However, it is important to emphasize that the populations
evaluated in these studies are not directly comparable to our population. While we evaluated
HIV-infected individuals accessing routine medical care at an ACTG-affiliated site,
Sullivan, et al assessed adults with HIV/AIDS who participated in a behavioral surveillance
study and the study by Gifford, et al analyzed trial participation in individuals enrolled in
the HIV Cost and Services Utilization Study, which constituted a representative sample of
HIV-infected patients receiving medical care. Limited knowledge of available studies is the
first barrier that prevents trial enrollment. Hispanics and AAs have historically been reported
to have less knowledge about the clinical trials for which they may be eligible.8,13 In some
instances, these limitations can be overcome by building multidisciplinary teams and
strategies aimed at fulfilling the needs of specific communities, but their general
applicability has yet to be evaluated.3,5,10,12
In addition to the limited knowledge about clinical trials, mistrust and fear towards medical
research can negatively influence study participation among minorities.1,7,14 Some of this
fear is rooted in historical events where fundamental ethical principles were violated in
research activities involving racial minorities,15,16,17 resulting in negative community
attitudes towards medical research. An example of this mistrust could be observed in our
study by the proportion of AAs and Hispanics who stated that studies were “not friendly” to
their race, and also by the proportion of these minority individuals who were concerned
about being a “guinea pig” or having their personal information disclosed without their
consent, which is consistent with previous observations in other studies.4,13 Importantly,
when previous trial participants were asked about their experience in an HIV/AIDS study,
we found no difference in the proportion of AAs or Hispanics vs. whites who reported
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negative feelings. This serves as a clear example of the disconnect between the preconceived
negative notions about medical research and the actual benefits of trial participation among
minority groups, a concern that requires intensive intervention from the research community
to improve minority participation.
Low levels of education and inadequate health literacy have been associated with
underrepresentation in clinical research.2,18 This association with education levels was
evident in our study by the proportion of individuals with a high school education or less
who were not aware about clinical trials and had never been approached to participate,
thought of participating, tried to participate or had participated in an HIV/AIDS study.
Language barriers, limited healthcare utilization, and an unstable immigration status may
also limit minority knowledge and intention to participate in clinical trials.2,19,20 Although
our study did not identify significant differences in participation in HIV/AIDS trials
according to first language (English vs. Spanish), we did observe a lack of knowledge about
available studies among Spanish speakers. Interestingly, Spanish speakers were not more
likely to report that they would avoid trial participation because they did not understand the
studies, which could be explained by the benefits of having a bilingual staff and informed
consents in Spanish available at many ACTG sites.
Research staff perceptions on minority participation are also a major factor that influence
trial enrollment. This could partially explain the small proportion of minority patients that
reported having ever been approached to participate in an HIV/AIDS clinical trial (66% AAs
and 73% Hispanics vs. 75% whites, p<0.001), which remained significant in the multivariate
analysis and is consistent with previous observations in HIV/AIDS and non-HIV/AIDS
studies.6,21,22 In a previous ACTG-based study, King, et al, showed that research personnel
could be biased against approaching AAs, Hispanics and non-English speakers into HIV/
AIDS clinical trials because these individuals may be perceived as being less interested in
study participation and also less likely to successfully enroll and stay in the study.21
Similarly, Wendler, et al, identified substantial differences by race and ethnicity in the
number of individuals invited to participate in clinical trials (some of which included HIV
infection).6 Among some of the reasons that could explain this bias are racial and gender
disparities that exist between the HIV/AIDS-affected population and the research personnel,
concerns for study and medication non-compliance, language barriers that can exist between
patients and researchers and some inaccurate preconceived notions that investigators may
have about racial minorities.23,24 This bias in recruitment has also been observed among
medical providers of HIV care, who are usually the main source of referrals for research
studies.3,25 Increasing minority participation in HIV/AIDS research requires increased
outreach for inclusion of underrepresented populations and assurance of access to health
research for all individuals, rather than a radical modification of minority attitudes.6 The
racial and ethnic diversification of the research and medical staff,26,27 in addition to the
engagement of previous minority study participants (and their communities), could prove a
useful strategy with a beneficial impact in minority recruitment and retention in clinical
trials, particularly if the research experience has been mostly positive, as found in our study.
We found that a majority of Hispanics and Spanish speakers believed that participating in a
study had made them healthier. This is an interesting finding that was also supported by the
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large proportion of Hispanics and Spanish speakers who identified the possibility of
obtaining “better healthcare” as a main reason to participate in a study. According to data
from the Pew Hispanic Center, approximately 31% of Hispanics in the US do not have
health insurance, which is almost double of the overall 16% of Americans without health
insurance.28 Participating in a clinical trial could be the only viable option for some HIV-
infected individuals to access any healthcare and life-saving medications and offers a unique
opportunity for newer, more effective strategies aimed at increasing enrollment in these
marginalized populations. Therefore, promoting clinical trial participation as an overall
health benefit and opportunity for improved medical care could be used as a successful
strategy to increase the enrollment of these disadvantage minorities.
Our study has some limitations. First, self-administered HIV/AIDS-related surveys carry an
inherent risk of reporting bias, barriers in communication, inaccurate disclosure of behaviors
and overestimation of favorable responses.29 Second, there may be overlap between ethnic
group, first language and level of education. Third, we excluded a small number of
participants in the “other/mixed” race category for whom we were unable to adjudicate race
due to the very small number of individuals in each group. Fourth, we actively targeted
minorities and women from within a population of HIV-infected patients being cared for at
ACTG sites that actively recruit for clinical trials, which carries the potential for selection
bias. While we understand that patients at these research-affiliated clinical sites may not be
representative of the general HIV-infected population and would be more likely to know
about HIV/AIDS clinical trials, we believe our study presents unique and novel results
because it identified notable racial disparities, even in a setting where all individuals had
direct access to research studies.
Conclusion
Representation of all racial and social backgrounds in HIV/AIDS clinical trials is important
to better understand treatment outcomes and identify issues that may be unique to some
populations. Our study describes underrepresentation of minorities in HIV-related studies
that may be promoted by a combination of the individual’s pre-conceived fear and mistrust
of medical research, the research staff biases related to enrollment of marginalized
populations and the limitations that the studies can impose to the inclusion of minority
individuals. Researchers should enhance their efforts to minimize research participation
disparities and improve recruitment from all ethnic and racial groups who are affected by
HIV/AIDS in the US.
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Table 1
Demographics of survey participants (N=2,175).
Characteristic N (%)
Race
  White 677 (31)
  African- American 871 (40)
  Hispanic 445 (20)
  Other/Mixed 125 (6)
  No response 57 (3)
Gender
  Male 1,546 (71)
  Female 573 (26)
  Transgender (MTF) 13 (1)
  No response 43 (2)
First Language
  English 1,748 (80)
  Spanish 292 (13)
  Other 31 (1)
  No response 104 (5)
Level of Education
  Elementary 153 (7)
  High School 678 (31)
  Some College/Technical 672 (31)
  College/Graduate 618 (28)
  No response 54 (2)
Employment*
  Not employed 618 (28)
  Part-time employment 296 (14)
  Full-time employment 608 (28)
  Homemaker 89 (4)
  Disabled 604 (28)
  Student 110 (5)
  Retired 104 (5)
Tobacco use (any within last year) 873 (40)
Alcohol use (any within last month) 865 (40)
  ≥5 drinks in a row at least once 636 (29)
Illicit drug use (any within last year)
  Marijuana 553 (25)
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Characteristic N (%)
  Other‡ 256 (12)
MTF=Male-to-female.
*
Proportions are not mutually exclusive and may add to >100%.
‡
Includes cocaine, heroin and amphetamines.
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Table 5
Factors associated with being talked to about participating in an HIV/AIDS clinical trial.
Unadjusted OR (95% CI) Adjusted OR
(95% CI)a
Race
  White ref Ref
  African-American 0.65 (0.52, 0.81)b 0.70 (0.55, 0.89)b
  Hispanic 0.65 (0.49, 0.85)b 0.69 (0.47, 1.02)c
  Mixed race or other race 0.75 (0.49, 1.14)d 0.79 (0.51, 1.22)d
Education
  Elementary school ref ref
  High school 1.18 (0.82, 1.71)d 1.18 (0.81, 1.73)d
  Some college or technical school 1.67 (1.15, 2.43)b 1.57 (1.06, 2.33)b
  College or graduate school 1.89 (1.29, 2.77)b 1.68 (1.12, 2.51)b
First language
  English ref Ref
  Spanish 0.86 (0.66, 1.12)d 1.08 (0.71, 1.64)d
  Other 0.63 (0.30, 1.32)d 0.61 (0.28, 1.29)d
Last use of tobacco
  Never/more than a year ago ref Ref
  Within past year or past month 0.78 (0.64, 0.94)b 0.81 (0.65, 0.98)b
Age categories (years)
  Under 25 ref ref
  25–34 0.93 (0.52, 1.67)d 0.89 (0.49, 1.61)d
  35–44 0.72 (0.42, 1.26)d 0.67 (0.38, 1.18)d
  45–54 0.74 (0.43, 1.27)d 0.67 (0.39, 1.17)d
  ≥55 0.89 (0.51, 1.58)d 0.78 (0.43, 1.38)d
Sex
  Male ref ref
  Female 1.03 (0.84, 1.27)d 1.19 (0.95, 1.49)d
Alcohol use (intermittent)
  Never/once a month ref
  >2–3 times per month 1.21 (0.99 to 1.47)c
Alcohol use (binge)
  Never/once a month ref
  >2–3 times per month 0.86 (0.67 to 1.10)d
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Unadjusted OR (95% CI) Adjusted OR
(95% CI)a
Marijuana use
  Never/more than 1 year ago ref
  Within past month/year 1.03 (0.83 to 1.28)d
Other drug use (cocaine, heroin,
amphetamines)
  Never/more than 1 year ago ref
  Within past month/year 0.97 (0.72 to 1.29)d
a
Adjusted ORs are from a multivariable model that includes age, education, sex, race, first language and tobacco use. The multivariable (adjusted)







HIV Clin Trials. Author manuscript; available in PMC 2015 January 01.
